X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PFIZER - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PFIZER IPCA LABS/
PFIZER
 
P/E (TTM) x 30.4 38.4 79.2% View Chart
P/BV x 3.6 5.6 63.9% View Chart
Dividend Yield % 0.1 0.6 21.6%  

Financials

 IPCA LABS   PFIZER
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PFIZER
Mar-18
IPCA LABS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6952,365 29.4%   
Low Rs4001,625 24.6%   
Sales per share (Unadj.) Rs260.2430.3 60.5%  
Earnings per share (Unadj.) Rs19.078.7 24.1%  
Cash flow per share (Unadj.) Rs33.193.2 35.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.21.0 18.2%  
Book value per share (Unadj.) Rs213.0586.5 36.3%  
Shares outstanding (eoy) m126.2045.75 275.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.6 45.4%   
Avg P/E ratio x28.925.3 113.9%  
P/CF ratio (eoy) x16.621.4 77.4%  
Price / Book Value ratio x2.63.4 75.6%  
Dividend payout %5.325.4 20.7%   
Avg Mkt Cap Rs m69,12091,271 75.7%   
No. of employees `00013.32.6 504.0%   
Total wages/salary Rs m7,3593,143 234.1%   
Avg. sales/employee Rs Th2,477.47,484.8 33.1%   
Avg. wages/employee Rs Th555.21,195.0 46.5%   
Avg. net profit/employee Rs Th180.61,369.1 13.2%   
INCOME DATA
Net Sales Rs m32,83619,685 166.8%  
Other income Rs m4181,143 36.6%   
Total revenues Rs m33,25420,828 159.7%   
Gross profit Rs m4,5055,003 90.0%  
Depreciation Rs m1,777663 268.3%   
Interest Rs m2404 5,719.0%   
Profit before tax Rs m2,9055,479 53.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,878 27.2%   
Profit after tax Rs m2,3943,601 66.5%  
Gross profit margin %13.725.4 54.0%  
Effective tax rate %17.634.3 51.3%   
Net profit margin %7.318.3 39.9%  
BALANCE SHEET DATA
Current assets Rs m19,45524,167 80.5%   
Current liabilities Rs m10,0769,544 105.6%   
Net working cap to sales %28.674.3 38.5%  
Current ratio x1.92.5 76.3%  
Inventory Days Days9855 177.7%  
Debtors Days Days6729 233.2%  
Net fixed assets Rs m20,2609,514 213.0%   
Share capital Rs m252458 55.2%   
"Free" reserves Rs m26,63326,375 101.0%   
Net worth Rs m26,88626,832 100.2%   
Long term debt Rs m2,34025 9,360.4%   
Total assets Rs m41,17336,900 111.6%  
Interest coverage x13.11,305.5 1.0%   
Debt to equity ratio x0.10 9,341.7%  
Sales to assets ratio x0.80.5 149.5%   
Return on assets %6.49.8 65.5%  
Return on equity %8.913.4 66.4%  
Return on capital %10.820.4 52.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64222 69,830.8%   
Fx outflow Rs m4,8841,489 328.0%   
Net fx Rs m10,759-1,466 -733.7%   
CASH FLOW
From Operations Rs m3,4113,318 102.8%  
From Investments Rs m-1,354-2,383 56.8%  
From Financial Activity Rs m-1,304-1,104 118.2%  
Net Cashflow Rs m753-169 -447.0%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.4 7.5 152.0%  
FIIs % 25.3 4.9 516.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.7 73.4%  
Shareholders   36,892 85,207 43.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 18, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - SHASUN PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS